|
1
|
Rastrelli M, Tropea S, Rossi CR and
Alaibac M: Melanoma: Epidemiology, risk factors, pathogenesis,
diagnosis and classification. Vivo. 28:1005–1011. 2014.
|
|
2
|
National Collaborating Centre for Cancer.
Melanoma: Assessment and management. National Institute for Health
and Care Excellence; London: 2015
|
|
3
|
Tripp MK, Watson M, Balk SJ, Swetter SM
and Gershenwald JE: State of the science on prevention and
screening to reduce melanoma incidence and mortality: The time is
now. CA Cancer J Clin. May 27–2016.(Epub ahead of print).
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoek KS, Eichhoff OM, Schlegel NC,
Döbbeling U, Kobert N, Schaerer L, Hemmi S and Dummer R: In vivo
switching of human melanoma cells between proliferative and
invasive states. Cancer Res. 68:650–656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scolyer RA, Li LX, McCarthy SW, Shaw HM,
Stretch JR, Sharma R and Thompson JF: Immunohistochemical stains
fail to increase the detection rate of micrometastatic melanoma in
completion regional lymph node dissection specimens. Melanoma Res.
14:263–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fleming JM, Ginsburg E, Oliver SD,
Goldsmith P and Vonderhaar BK: Hornerin, an S100 family protein, is
functional in breast cells and aberrantly expressed in breast
cancer. BMC Cancer. 12:2662012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nipp M, Elsner M, Balluff B, Meding S,
Sarioglu H, Ueffing M, Rauser S, Unger K, Höfler H, Walch A, et al:
S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary
thyroid carcinoma with lymph node metastasis identified by MALDI
imaging. J Mol Med (Berl). 90:163–174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hilly O, Koren R, Raz R, RathWolfson L,
Mizrachi A, Hamzany Y, Bachar G and Shpitzer T: The role of
s100-positive dendritic cells in the prognosis of papillary thyroid
carcinoma. Am J Clin Pathol. 139:87–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bishop PW, Menasce LP, Yates AJ, Win NA
and Banerjee SS: An immunophenotypic survey of malignant melanomas.
Histopathology. 23:159–166. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao Z, Stanek A and Chen S: A metastatic
melanoma with an unusual immunophenotypic profile. Am J
Dermatopathol. 29:169–171. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carreira S, Goodall J, Denat L, Rodriguez
M, Nuciforo P, Hoek KS, Testori A, Larue L and Goding CR: Mitf
regulation of Dia1 controls melanoma proliferation and
invasiveness. Genes Dev. 20:3426–3439. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lekmine F, Chang CK, Sethakorn N, Das
Gupta TK and Salti GI: Role of microphthalmia transcription factor
(Mitf) in melanoma differentiation. Biochem Biophys Res Commun.
354:830–835. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Granter SR, Weilbaecher KN, Quigley C and
Fisher DE: Role for microphthalmia transcription factor in the
diagnosis of metastatic malignant melanoma. Appl Immunohistochem
Mol Morphol. 10:47–51. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miettinen M, Fernandez M, Franssila K,
Gatalica Z, Lasota J and Sarlomo-Rikala M: Microphthalmia
transcription factor in the immunohistochemical diagnosis of
metastatic melanoma: comparison with four other melanoma markers.
Am J Surg Pathol. 25:205–211. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hague A, Moorghen M, Hicks D, Chapman M
and Paraskeva C: BCL-2 expression in human colorectal adenomas and
carcinomas. Oncogene. 9:3367–3370. 1994.PubMed/NCBI
|
|
16
|
Barnhill RL and Mihm MC Jr: The
histopathology of cutaneous malignant melanoma. Semin Diagn Pathol.
10:47–75. 1993.PubMed/NCBI
|
|
17
|
Cochran AJ, Holland GN, Wen DR, Herschman
HR, Lee WR, Foos RY and Straatsma BR: Detection of cytoplasmic
S-100 protein in primary and metastatic intraocular melanomas.
Invest Ophthalmol Vis Sci. 24:1153–1155. 1983.PubMed/NCBI
|
|
18
|
Gown AM, Vogel AM, Hoak D, Gough F and
McNutt MA: Monoclonal antibodies specific for melanocytic tumors
distinguish subpopulations of melanocytes. Am J Pathol.
123:195–203. 1986.PubMed/NCBI
|
|
19
|
Denat L and Larue L: Malignant melanoma
and the role of the paradoxal protein Microphthalmia transcription
factor. Bull Cancer. 94:81–92. 2007.(In French). PubMed/NCBI
|
|
20
|
Koludrovic D and Davidson I: MITF, the
Janus transcription factor of melanoma. Future Oncol. 9:235–244.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nonaka D, Laser J, Tucker R and Melamed J:
Immunohistochemical evaluation of necrotic malignant melanomas. Am
J Clin Pathol. 127:787–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ugurel S, Houben R, Schrama D, Voigt H,
Zapatka M, Schadendorf D, Bröcker EB and Becker JC:
Microphthalmia-associated transcription factor gene amplification
in metastatic melanoma is a prognostic marker for patient survival,
but not a predictive marker for chemosensitivity and chemotherapy
response. Clin Cancer Res. 13:6344–6350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
King R, Googe PB, Weilbaecher KN, Mihm MC
Jr and Fisher DE: Microphthalmia transcription factor expression in
cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
Am J Surg Pathol. 25:51–57. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nybakken GE, Sargen M, Abraham R, Zhang
PJ, Ming M and Xu X: MITF accurately highlights epidermal
melanocytes in atypical intraepidermal melanocytic proliferations.
Am J Dermatopathol. 35:25–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
